Factors impacting performance on the 6-minute walk test by people with late-onset Pompe disease.
biomarker
evaluation
gait
neuromuscular disorder
primary endpoint
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
23
03
2022
received:
21
06
2021
accepted:
26
03
2022
pubmed:
2
4
2022
medline:
24
5
2022
entrez:
1
4
2022
Statut:
ppublish
Résumé
Pompe disease is a progressive myopathy that combines motor, respiratory, and cardiac impairments. The 6-min walk test is the gold standard for assessing disease severity at the motor level. The objective of this study was to better determine the parameters that influence the total distance covered in patients with Pompe disease. We performed a retrospective review of 15 patients with late-onset Pompe disease who were followed regularly at a single referral center. Logistic regression was used to investigate the links between motor, respiratory and cardiac variables and 6-min walk test performance. When considering baseline clinical and demographic variables, a seven-step backward elimination regression analysis yielded a model with two predictors (age and the use of an assistive device) that explained 85.5% of the variance. When considering the cardiorespiratory variables monitored during gait, a three-step backward elimination regression analysis showed that two predictors (heart rate recovery and the baseline partial pressure of carbon dioxide) explained 42.2% of the variance. Our results highlighted the importance of respiratory and cardiac adaptation during exercise (along with motor ability) during the 6-min walk test in patients with Pompe disease. Further studies of larger cohorts are necessary to validate the model, which might enable investigators to determine whether intra-individual fluctuations in 6-min walk test performance are related to physiological parameters and/or to other variables such as the patient's level of motivation during the test.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
693-697Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Semplicini C, Letard P, De Antonio M, et al. Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study. J Inherit Metab Dis. 2018;41:937-946. doi:10.1007/s10545-018-0243-7
Schoser B, Stewart A, Kanters S, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264:621-630. doi:10.1007/s00415-016-8219-8
Gibbons WJ, Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetition 6-min walk test in healthy adults older than 20 years. J Cardpulm Rehabil. 2001;21:87-93. doi:10.1097/00008483-200103000-00005
Kervio G, Carre F, Ville NS. Reliability and intensity of the six-minute walk test in healthy elderly subjects. Med Sci Sports Exerc. 2003;35:169-174. doi:10.1097/00005768-200301000-00025
Camarri B, Eastwood PR, Cecins NM, Thompson PJ, Jenkins S. Six minute walk distance in healthy subjects aged 55-75 years. Respir Med. 2006;100:658-665. doi:10.1016/j.rmed.2005.08.003
Kierkegaard M, Tollbäck A. Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscul Disord NMD. 2007;17:943-949. doi:10.1016/j.nmd.2007.08.003
Wu G, Sanderson B, Bittner V. The 6-minute walk test: how important is the learning effect? Am Heart J. 2003;146:129-133. doi:10.1016/S0002-8703(03)00119-4
Brown AW, Nathan SD. The value and application of the 6-minute-walk test in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2018;15:3-10. doi:10.1513/AnnalsATS.201703-244FR
Prahm KP, Witting N, Vissing J. Decreased variability of the 6-minute walk test by heart rate correction in patients with neuromuscular disease. PLoS One. 2014;9:e114273. doi:10.1371/journal.pone.0114273
Weir NA, Brown AW, Shlobin OA, et al. The influence of alternative instruction on 6-min walk test distance. Chest. 2013;144:1900-1905. doi:10.1378/chest.13-0287
Montes J, McDermott MP, Martens WB, et al. Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010;74:833-838. doi:10.1212/WNL.0b013e3181d3e308
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117. doi:10.1164/ajrccm.166.1.at1102
Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428-1446. doi:10.1183/09031936.00150314
Terzis G, Dimopoulos F, Papadimas GK, et al. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2011;104:279-283. doi:10.1016/j.ymgme.2011.05.013
Terzis G, Krase A, Papadimas G, Papadopoulos C, Kavouras SA, Manta P. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2012;107:669-673. doi:10.1016/j.ymgme.2012.10.020
du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183:1231-1237. doi:10.1164/rccm.201007-1179OC
Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:1084-1090. doi:10.1164/rccm.200302-219OC
Nathan SD, du Bois RM, Albera C, et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109:914-922. doi:10.1016/j.rmed.2015.04.008